Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| NGEN | 6-K | bullish | 5/10 | NervGen reported Q1 2026 results with a net loss of $1.7M, improved from $3.9M a year ago due to non-cash warrant gains, | May 18, 2026 |
| GILD | 424B5 | neutral | 4/10 | Gilead Sciences is issuing $3.0 billion in senior unsecured notes across four tranches (2028-2034), with net proceeds of | May 18, 2026 |
| COLL | CLUSTER | neutral | 3/10 | Two directors at Collegium Pharmaceutical sold a combined $485K in open-market stock within 11 days of the company repor | May 18, 2026 |
| QUCY | 8-K | mixed | 7/10 | Quantum Cyber N.V. (QUCY) announced three major items on May 12, 2026: (1) a definitive Intellectual Property License Ag | May 18, 2026 |
| CMND | 6-K | bearish | 7/10 | Clearmind Medicine announced the issuance of $600,000 in convertible promissory notes at a 10% discount (net proceeds $5 | May 18, 2026 |
| SLNCF | S-3 | bearish | 6/10 | Silence Therapeutics filed a $300M universal shelf registration statement on Form S-3, including an at-the-market (ATM) | May 18, 2026 |
| MLYS | PRESS-RELEASE | neutral | 4/10 | Mineralys Therapeutics announced that new data from its Phase 3 LAUNCH-HTN trial of lorundrostat in patients with uncont | May 18, 2026 |
| MIRM | 8-K | mixed | 6/10 | Mirum issued $690.0M of 0.00% convertible senior notes due 2032, including the full $90M greenshoe. In privately negotia | May 18, 2026 |
| TEVA | CLUSTER | neutral | 2/10 | TEVA insiders sold $5.66M in stock on May 14, 2026, led by CFO Eliyahu Sharon Kalif ($5.46M). The sales occurred at ~$35 | May 18, 2026 |
| CMND | 6-K | neutral | 4/10 | Clearmind Medicine announced a preclinical research agreement with Hebrew University to study its lead compound MEAI (CM | May 18, 2026 |
| HYEX | 8-K | neutral | 5/10 | Healthy Extracts Inc. completed the acquisition of Adli Gummies Inc. (Imaras Beauty) on May 15, 2026, through its subsid | May 18, 2026 |
| ABBV | COURT-RULING | neutral | 3/10 | The Illinois Appellate Court affirmed summary judgment for AbbVie in a product liability case over its XEN gel stent. Th | May 18, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's submitted a 6-K filing enclosing the transcript of its Q4 FY2026 earnings call held on May 12, 2026. The fil | May 18, 2026 |
| UPB | PRESS-RELEASE | bullish | 7/10 | Upstream Bio presented positive Phase 2 VIBRANT trial data at ATS 2026, showing verekitug improved asthma control and na | May 18, 2026 |
| REGN | ANALYST-DOWNGRADE | bearish | 2/10 | On May 18, 2026, two firms downgraded Regeneron Pharmaceuticals (REGN). Citigroup cut from Buy to Neutral, slashed price | May 18, 2026 |
| SYBX | 25-NSE | bearish | 7/10 | Nasdaq has finalized the delisting of Synlogic, Inc. (SYBX) common stock, effective May 28, 2026, following a withdrawal | May 18, 2026 |
| AZN | 6-K | neutral | 2/10 | AstraZeneca filed a 6-K reporting the vesting of a performance share award to CEO Pascal Soriot on 14 May 2026. The awar | May 18, 2026 |
| HYFT | 6-K | neutral | 4/10 | MindWalk released a report documenting over 20 drug candidates originating from its antibody discovery work, with 10 pro | May 18, 2026 |
| AZN | 6-K | bullish | 7/10 | AstraZeneca announced FDA approval of Baxfendy (baxdrostat), a first-in-class aldosterone synthase inhibitor for adults | May 18, 2026 |
| AZN | 6-K | bullish | 7/10 | AstraZeneca announced FDA approval of Enhertu (trastuzumab deruxtecan) for two new indications in HER2-positive early br | May 18, 2026 |
| QNCX | 8-K | mixed | 7/10 | Quince Therapeutics (QNCX) has completed a reverse merger with Orphai Therapeutics, acquiring the private biotech in exc | May 18, 2026 |
| ISPC | DEFA14A | bearish | 6/10 | iSpecimen Inc. filed a DEFA14A urging shareholders to vote ahead of its repeatedly adjourned 2025 Annual Meeting, now se | May 18, 2026 |
| ASRT | 8-K | bullish | 8/10 | Assertio Holdings announced it has entered into a definitive merger agreement with Zydus Worldwide DMCC, under which Zyd | May 18, 2026 |
| XOMAP | DEFA14A | neutral | 4/10 | XOMA Royalty Corp filed a DEFA14A (definitive additional proxy soliciting material) disclosing Amendment No. 1 to its Ag | May 18, 2026 |
| SLNO | 8-K, 25-NSE | bullish | 8/10 | Neurocrine Biosciences completed its acquisition of Soleno Therapeutics on May 18, 2026, paying $53.00 per share in cash | May 18, 2026 |
| NBIX | 8-K | bullish | 7/10 | Neurocrine Biosciences closed its $2.9B acquisition of Soleno Therapeutics on May 18, 2026, adding VYKAT XR (diazoxide c | May 18, 2026 |
| LGNYZ | DEFA14A | neutral | 4/10 | Ligand Pharmaceuticals filed a DEFA14A (also structured as an 8-K) to report Amendment No. a minor administrative amend | May 18, 2026 |
| LGNYZ | 8-K | neutral | 3/10 | Ligand Pharmaceuticals filed an 8-K reporting Amendment No. 1 to its Merger Agreement with XOMA Royalty Corporation. The | May 18, 2026 |
| SNYR | 8-K | bearish | 7/10 | Synergy CHC Corp. received a Nasdaq deficiency notice on May 15, 2026, for failing to maintain the $1.00 minimum bid pri | May 18, 2026 |
| MTVA | 8-K | neutral | 4/10 | MetaVia Inc. announced that three late-breaking abstracts on its cardiometabolic assets DA-1726 (GLP-1/glucagon dual ago | May 18, 2026 |